CVE:IPA

ImmunoPrecise Antibodies Competitors

C$13.58
-1.07 (-7.30 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
C$13.58
Now: C$13.58
C$14.85
50-Day Range
C$10.99
MA: C$14.45
C$17.50
52-Week Range
C$3.75
Now: C$13.58
C$26.25
Volume25,818 shs
Average Volume64,158 shs
Market CapitalizationC$259.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ImmunoPrecise Antibodies (CVE:IPA) Vs. BLU, TH, NRI, PLI, MDNA, and NEPT

Should you be buying IPA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to ImmunoPrecise Antibodies, including BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), ProMetic Life Sciences (PLI), Medicenna Therapeutics (MDNA), and Neptune Wellness Solutions (NEPT).

BELLUS Health (TSE:BLU) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares BELLUS Health and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BELLUS HealthN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BELLUS Health and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BELLUS Health01202.67
ImmunoPrecise Antibodies0000N/A

Earnings & Valuation

This table compares BELLUS Health and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BELLUS HealthC$15,000.0029,559.16C$-42,145,306.00C($0.54)-10.52
ImmunoPrecise AntibodiesC$17.18 million15.08C$-4,082,906.00C($0.21)-63.46

ImmunoPrecise Antibodies has higher revenue and earnings than BELLUS Health. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Theratechnologies (TSE:TH) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Theratechnologies and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Earnings & Valuation

This table compares Theratechnologies and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$66.05 million6.48C$-34,627,329.00C($0.37)-12.36
ImmunoPrecise AntibodiesC$17.18 million15.08C$-4,082,906.00C($0.21)-63.46

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Theratechnologies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Theratechnologies and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
ImmunoPrecise Antibodies0000N/A

Theratechnologies currently has a consensus price target of C$3.75, indicating a potential downside of 17.76%. Given Theratechnologies' higher probable upside, research analysts clearly believe Theratechnologies is more favorable than ImmunoPrecise Antibodies.

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Earnings and Valuation

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.35C$-6,980,844.00C($0.61)-58.36
ImmunoPrecise AntibodiesC$17.18 million15.08C$-4,082,906.00C($0.21)-63.46

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Nuvo Pharmaceuticals Inc. (NRI.TO). ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals Inc. (NRI.TO), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and ImmunoPrecise Antibodies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00
ImmunoPrecise Antibodies0000N/A

ProMetic Life Sciences (TSE:PLI) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Profitability

This table compares ProMetic Life Sciences and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Earnings & Valuation

This table compares ProMetic Life Sciences and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
ImmunoPrecise AntibodiesC$17.18 million15.08C$-4,082,906.00C($0.21)-63.46

ImmunoPrecise Antibodies has lower revenue, but higher earnings than ProMetic Life Sciences. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for ProMetic Life Sciences and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
ImmunoPrecise Antibodies0000N/A

Medicenna Therapeutics (TSE:MDNA) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Medicenna Therapeutics and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicenna TherapeuticsN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Valuation and Earnings

This table compares Medicenna Therapeutics and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/AN/AC($0.31)-16.41
ImmunoPrecise AntibodiesC$17.18 million15.08C$-4,082,906.00C($0.21)-63.46

Medicenna Therapeutics has higher earnings, but lower revenue than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Medicenna Therapeutics and ImmunoPrecise Antibodies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicenna Therapeutics0000N/A
ImmunoPrecise Antibodies0000N/A

Summary

ImmunoPrecise Antibodies beats Medicenna Therapeutics on 2 of the 3 factors compared between the two stocks.

Neptune Wellness Solutions (TSE:NEPT) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Neptune Wellness Solutions and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neptune Wellness SolutionsN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Valuation and Earnings

This table compares Neptune Wellness Solutions and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neptune Wellness SolutionsC$52.78 million4.89C$-223,415,550.00C($1.35)-1.16
ImmunoPrecise AntibodiesC$17.18 million15.08C$-4,082,906.00C($0.21)-63.46

ImmunoPrecise Antibodies has lower revenue, but higher earnings than Neptune Wellness Solutions. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Neptune Wellness Solutions and ImmunoPrecise Antibodies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neptune Wellness Solutions00103.00
ImmunoPrecise Antibodies0000N/A

Neptune Wellness Solutions currently has a consensus price target of C$4.63, suggesting a potential upside of 196.47%. Given Neptune Wellness Solutions' higher possible upside, equities analysts clearly believe Neptune Wellness Solutions is more favorable than ImmunoPrecise Antibodies.

Summary

Neptune Wellness Solutions beats ImmunoPrecise Antibodies on 4 of the 7 factors compared between the two stocks.


ImmunoPrecise Antibodies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BLU
BELLUS Health
0.5$5.66-2.8%C$443.39 millionC$15,000.00-10.52Gap Up
Theratechnologies logo
TH
Theratechnologies
0.7$4.56-6.1%C$427.92 millionC$66.05 million-12.36News Coverage
Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.78-0.1%C$407.41 millionC$76.09 million-58.36
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22News Coverage
MDNA
Medicenna Therapeutics
0.5$5.07-1.2%C$268.21 millionN/A-16.41News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.56-4.5%C$258.17 millionC$52.78 million-1.16
EMC
Emblem
0.5$1.88-1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.49-1.1%C$236.31 millionC$3,000.00-6.04Gap Down
ATE
Antibe Therapeutics
1.3$4.58-0.4%C$208.42 millionC$9.33 million-5.82
ONC
Oncolytics Biotech
1.2$3.86-2.8%C$203.69 millionN/A-6.89Analyst Report
RVX
Resverlogix
0.7$0.87-1.1%C$203.57 millionN/A79.09Upcoming Earnings
Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.51-4.1%C$195.28 millionC$170,000.00-7.84
HBP
Helix BioPharma
0.5$0.88-3.4%C$124.20 millionN/A-16.00Gap Down
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.59-0.0%C$88.79 millionC$81,000.0017.35Gap Up
NVH
Novoheart
0.5$0.53-1.9%C$79.23 millionC$423,500.00-13.95
PDP
Pediapharm
0.5$0.30-1.7%C$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.60-1.7%C$65.67 millionC$11.64 million-11.76Gap Down
SBM
Sirona Biochem
0.5$0.35-5.7%C$58.80 millionC$123,870.00-26.92
PMN
ProMIS Neurosciences
0.5$0.17-11.8%C$52.01 millionC$1,787.00-8.50Gap Up
COV
Covalon Technologies
0.6$1.43-0.0%C$37.44 millionC$23.84 million-6.01Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27-3.7%C$34.02 millionC$13.02 million-0.39
IGX
IntelGenx Technologies
0.9$0.60-10.0%C$30.87 millionC$1.54 million-9.23High Trading Volume
QPT
Quest PharmaTech
0.8$0.10-10.5%C$21.76 millionC$38,871.000.15High Trading Volume
Gap Down
CZO
Ceapro
0.7$0.78-0.0%C$21.65 millionC$16.14 million23.64Gap Up
CTX
Crescita Therapeutics
0.6$0.84-1.2%C$17.34 millionC$15.64 million420.00
KNE
Kane Biotech
0.4$0.16-0.0%C$14.12 millionC$1.34 million-4.57Gap Down
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.10-5.3%C$12.70 millionN/A-4.32Gap Down
NSP
Naturally Splendid Enterprises
0.6$0.06-8.3%C$11.06 millionC$2.03 million-1.40Gap Up
MPH
Medicure
0.7$1.58-1.3%C$10.80 millionC$12.71 million-1.02
BTI
Bioasis Technologies
0.7$0.39-1.3%C$10.16 millionC$4.12 million35.00
HEM
Hemostemix
0.6$0.45-2.2%C$9.07 millionN/A-2.68Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.37-1.4%C$6.94 millionC$5.60 million6.76News Coverage
Gap Down
IOT
Innovotech
0.8$0.15-3.3%C$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$4.00-12.5%C$4.48 millionN/A-1.29High Trading Volume
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$45.95-3.2%C$0.00C$267.59 million50.49
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66News Coverage
Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Down
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.